Tandem Diabetes claims 2027 projections will determine stock performance
TNDMMMEDPODD
Statements (2)
- Neutral
Tandem Diabetes (TNDM) is a direct competitor to Insulet (PODD) and Minimed (MMED) in the insulin pump market.
- Neutral
Tandem Diabetes (TNDM) claims its 2027 projections will determine the stock's performance.